Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $9.92 down -6.42% from its previous closing price of $10.60. In other words, the price has decreased by -$6.42 from its previous closing price. On the day, 1.59 million shares were traded. OCUL stock price reached its highest trading level at $10.735 during the session, while it also had its lowest trading level at $9.82.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.55 and its Current Ratio is at 16.64. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
On June 20, 2024, TD Cowen Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $7 to $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 16 ’24 when PHILIP C. STRASSBURGER bought 13,125 shares for $10.23 per share.
Nayak Sanjay sold 1,832 shares of OCUL for $16,525 on Aug 23 ’24. The Chief Strategy Officer now owns 176,194 shares after completing the transaction at $9.02 per share. On Aug 23 ’24, another insider, Dugel Pravin, who serves as the insider of the company, sold 20,880 shares for $9.02 each. As a result, the insider received 188,338 and left with 812,473 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1546746240 and an Enterprise Value of 1161941120. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.31 while its Price-to-Book (P/B) ratio in mrq is 4.09. Its current Enterprise Value per Revenue stands at 19.018 whereas that against EBITDA is -10.492.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $2.05. The 50-Day Moving Average of the stock is 0.58%, while the 200-Day Moving Average is calculated to be 23.91%.
Shares Statistics:
For the past three months, OCUL has traded an average of 1.09M shares per day and 835870 over the past ten days. A total of 155.92M shares are outstanding, with a floating share count of 134.99M. Insiders hold about 13.42% of the company’s shares, while institutions hold 80.76% stake in the company. Shares short for OCUL as of 1730332800 were 12671361 with a Short Ratio of 11.64, compared to 1727654400 on 16194368. Therefore, it implies a Short% of Shares Outstanding of 12671361 and a Short% of Float of 8.1599995.
Earnings Estimates
The current market rating for Ocular Therapeutix Inc (OCUL) reflects the collective analysis of 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.89 and -$1.22 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$1.02, with 3.0 analysts recommending between -$1.01 and -$1.04.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $17.39M this quarter.It ranges from a high estimate of $21.4M to a low estimate of $15.7M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $14.8MFor the next quarter, 9 analysts are estimating revenue of $17.05M. There is a high estimate of $18.23M for the next quarter, whereas the lowest estimate is $16M.
A total of 3 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $63.76M, while the lowest revenue estimate was $62.3M, resulting in an average revenue estimate of $63.02M. In the same quarter a year ago, actual revenue was $58.44MBased on 9 analysts’ estimates, the company’s revenue will be $74.29M in the next fiscal year. The high estimate is $86.11M and the low estimate is $65.2M.
